ici

[EN IMAGES] Vol spectaculaire: un guichet automatique extirpé d’une caisse Desjardins en Mauricie

Des voleurs ont réussi à dérober un guichet automatique en le tirant à travers la devanture vitrée de l’immeuble à l’aide d’un camion.




ici

Les White Stripes abandonnent les poursuites judiciaires contre Donald Trump

Les White Stripes ont abandonné leur plainte sur les droits d'auteur contre le président des États-Unis nouvellement réélu, Donald Trump.




ici

ALP told to ‘get better policies’

A review of Labor’s City of Sydney council campaign finds earlier preselections and better policies are needed.




ici

Les légumes d’ici, toute l’année

Si octobre célèbre la fin des récoltes, plusieurs légumes demeurent disponibles lors de la saison froide.




ici

Indian health, pharma companies invited to participate in Iraq's 'Medico Expo' from Feb 5─8, 2025

The Embassy of India in Iraq has extended an invitation to Indian businesses to participate in the "Medico Expo," officially known as the Erbil International Health Exhibition. This prestigious event, set to be the




ici

Qsight Prospector: boosting sales efficiency

In this episode you can hear Olivia Friett, editor of Medical Plastics News talk to Erik Haines, managing director at Guidepoint Qsight where we will discuss Qsight Prospector, a data-driven sales intelligence programme.




ici

How the 2024 Election Could Change Access to Health Care in the U.S. and Influence Global Nuclear Policies

The outcome of the 2024 U.S. presidential election could reshape policies from health care at home to nuclear proliferation abroad




ici

Clean Energy Is Bringing Electricity to Many in the Navajo Nation

Thousands of homes in Navajo and other tribal lands don’t have access to electricity. A $200-million federal funding effort aims to fix that problem with solar power and other clean energy




ici

The Myth that Musicians Die at 27 Shows How Superstitions Are Made

Famous people who die at age 27, such as Janis Joplin, Jimi Hendrix and Amy Winehouse, get even more famous because of the mythology surrounding that number—an example of how modern folklore emerges




ici

Drug Channels News Roundup, October 2024: Humira Price War Update, PA vs. Providers, IRA vs. Physicians, My AI Podcast, New DCI Jobs, and Dr. G on Copayments

Eeek! It's time for Drug Channels’ Halloween roundup of terrifying tales to share with your ghoulish fiends. This month’s tricks and treats:
  • Spooky! Blue Shield of California frightens away the gross-to-net bubble with its Humira biosimilar strategy
  • Vampiric! Prior authorization sinks its fangs into providers’ time
  • Wicked! How the IRA will put a stake through specialty physician practices
  • Eerie! Google’s monstrous AI podcasts leave me petrified
  • Zoinks! Join the vampire hunters at Drug Channels Institute
Plus, Dr. Glaucomflecken tells us a frightening tale of copayments.

P.S. Stretch out your arms and join the ever-growing zombie horde who shamble after me on LinkedIn. You’ll find my ghostly rantings along with commentary from the undead hordes in the DCI community.
Read more »
       




ici

Don’t Confuse the Art and Science of Medicine: PCI vs CABG for Left Main Disease

It is often said that medicine is both an art and a science. In an imperfect world this is both inevitable and desirable. But it is extremely important that the two should not be confused with each other. In particular, because the “science” side of the equation has achieved overwhelming prestige and authority, it is...

Click here to continue reading...




ici

Medicines for Europe 23rd Regulatory Affairs Conference 2025

<p> <b>23rd Regulatory Affairs Conference 202</b><b>5</b><br /> <b>27</b><b>‒</b><b>28 February 2025</b><br /> Hilton Amsterdam Airport Schiphol<br />Amsterdam, The Netherlands</p>




ici

Medicinal Chemistry In The Age Of Artificial Intelligence

By Peter Tummino, CSO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC  “Over the next five to 10 years, our goal is to become a company that’s leading the world in personalized medicines, a company

The post Medicinal Chemistry In The Age Of Artificial Intelligence appeared first on LifeSciVC.




ici

Will Your Family Make You a Better Trial Participant?

It is becoming increasing accepted within the research community that patient engagement leads to a host of positive outcomes – most importantly (at least practically speaking) improved clinical trial recruitment and retention.

But while we can all agree that "patient engagement is good" in a highly general sense, we don't have much consensus on what the implications of that idea might be. There is precious little hard evidence about how to either attract engaged patients, or how we might effectively turn "regular patients" into "engaged patients".

That latter point - that we could improve trial enrollment and completion rates by converting the (very large) pool of less-engaged patient - is a central tenet of the mHealth movement in clinical trials. Since technology can now accompany us almost anywhere, it would seem that we have an unprecedented opportunity to reach out and connect with current and potential trial participants.

However, there are signs that this promised revolution in patient engagement hasn't come about. From the decline of new apps being downloaded to the startlingly high rate of people abandoning their wearable health devices, there's a growing body of evidence suggesting that we aren't in fact making very good progress towards increasing engagement. We appear to have underestimated the inertia of the disengaged patient.

So what can we do? We know people like their technology, but if they're not using it to engage with their healthcare decisions, we're no better off as a result.

Daniel Calvert, in a recent blog post at Parallel 6 offers an intriguing solution: he suggests we go beyond the patient and engage their wider group of loved ones. By engaging what Calvert calls the Support Circle - those people most likely to "encourage the health and well being of that patient as they undergo a difficult period of their life" - trial teams will find themselves with a more supported, and therefore more engaged, participant, with corresponding benefits to enrollment and retention. 

Calvert outlines a number of potential mechanisms to get spouses, children, and other loved ones involved in the trial process:
During the consent process the patient can invite their support team in with them. A mobile application can be put on their phones enabling encouraging messages, emails, and texts to be sent. Loved ones can see if their companion or family member did indeed take today’s medication or make last Monday’s appointment. Gamification offers badges or pop-ups: “Two months of consecutive appointments attended” or “perfect eDiary log!” Loved ones can see those notifications, like/comment, and constantly encourage the patients. 
Supporting materials can also be included in the Support Circle application. There are a host of unknown terms to patients and their team. Glossaries, videos, FAQs, contact now, and so much more can be made available at their fingertips.
I have to admit I'm fascinated by Calvert's idea. I want him to be right: the picture of supportive, encouraging, loving spouses and children standing by to help a patient get through a clinical trial is an attractive one. So is the idea that they're just waiting for us to include them - all we need to do is a bit of digital communication with them to get them fully on board as members of the study team.

The problem, however, remains: we have absolutely no evidence that this approach will work. There is no data showing that it is superior to other approaches to engage trial patients.

(In fact, we may even have some indirect evidence that it may hinder enrollment: in trials that require active caregiver participation, such as those in Alzheimer's Disease, caregivers are believed to often contribute to the barriers to patient enrollment).

Calvert's idea is a good one, and it's worthy of consideration. More importantly, it's worthy of being rigorously tested against other recruitment and retention approaches. We have a lot of cool new technologies, and even more great ideas - we're not lacking for those. What we're lacking is hard data showing us how these things perform. What we especially need is comparative data showing how new tactics work relative to other approaches.

Over 5 years ago, I wrote a blog post bemoaning the sloppy approaches we take in trial recruitment - a fact made all the more painfully ironic by the massive intellectual rigor of the trials themselves. I'm not at all sure that we've made any real progress in those 5 years.

In my next post, I'll outline what I believe are some of the critical steps we need to take to improve the current situation, and start bringing some solid evidence to the table along with our ideas.

[Photo credit: Flikr user Matthew G, "Love (of technology)"]







ici

Scary Stories: Establishing a Field Amid Skepticism



In the spirit of the Halloween season, IEEE Spectrum presents a pair of stories that—although grounded in scientific truth rather than the macabre—were no less harrowing for those who lived them. In today’s installment, Robert Langer had to push back against his field’s conventional wisdom to pioneer a drug-delivery mechanism vital to modern medicine.

Nicknamed the Edison of Medicine, Robert Langer is one of the world’s most-cited researchers, with over 1,600 published papers, 1,400 patents, and a top-dog role as one of MIT’s nine prestigious Institute Professors. Langer pioneered the now-ubiquitous drug delivery systems used in modern cancer treatments and vaccines, indirectly saving countless lives throughout his 50-year career.

But, much like Edison and other inventors, Langer’s big ideas were initially met with skepticism from the scientific establishment.

He came up in the 1970s as a chemical engineering postdoc working in the lab of Dr. Judah Folkman, a pediatric surgeon at the Boston Children’s Hospital. Langer was tasked with solving what many believed was an impossible problem—isolating angiogenesis inhibitors to halt cancer growth. Folkman’s vision of stopping tumors from forming their own self-sustaining blood vessels was compelling enough, but few believed it possible.

Langer encountered both practical and social challenges before his first breakthrough. One day, a lab technician accidentally spilled six months’ worth of samples onto the floor, forcing him to repeat the painstaking process of dialyzing extracts. Those months of additional work steered Langer’s development of novel microspheres that could deliver large molecules of medicine directly to tumors.

In the 1970s, Langer developed these tiny microspheres to release large molecules through solid materials, a groundbreaking proof-of-concept for drug delivery.Robert Langer

Langer then submitted the discovery to prestigious journals and was invited to speak at a conference in Michigan in 1976. He practiced the 20-minute presentation for weeks, hoping for positive feedback from respected materials scientists. But when he stepped off the podium, a group approached him and said bluntly, “We don’t believe anything you just said.” They insisted that macromolecules were simply too large to pass through solid materials, and his choice of organic solvents would destroy many inputs. Conventional wisdom said so.

Nature published Langer’s paper three months later, demonstrating for the first time that non-inflammatory polymers could enable the sustained release of proteins and other macromolecules. The same year, Science published his isolation mechanism to restrict tumor growth.

Langer and Folkman’s research paved the way for modern drug delivery.MIT and Boston Children’s Hospital

Even with impressive publications, Langer still struggled to secure funding for his work in controlling macromolecule delivery, isolating the first angiogenesis inhibitors, and testing their behavior. His first two grant proposals were rejected on the same day, a devastating blow for a young academic. The reviewers doubted his experience as “just an engineer” who knew nothing about cancer or biology. One colleague tried to cheer him up, saying, “It’s probably good those grants were rejected early in your career. Since you’re not supporting any graduate students, you don’t have to let anyone go.” Langer thought the colleague was probably right, but the rejections still stung.

His patent applications, filed alongside Folkman at the Boston Children’s Hospital, were rejected five years in a row. After all, it’s difficult to prove you’ve got something good if you’re the only one doing it. Langer remembers feeling disappointed but not crushed entirely. Eventually, other scientists cited his findings and expanded upon them, giving Langer and Folkman the validation needed for intellectual property development. As of this writing, the pair’s two studies from 1976 have been cited nearly 2,000 times.

As the head of MIT’s Langer Lab, he often shares these same stories of rejection with early-career students and researchers. He leads a team of over 100 undergrads, grad students, postdoctoral fellows, and visiting scientists, all finding new ways to deliver genetically engineered proteins, DNA, and RNA, among other research areas. Langer’s reputation is further bolstered by the many successful companies he co-founded or advised, like mRNA leader Moderna, which rose to prominence after developing its widely used COVID-19 vaccine.

Langer sometimes thinks back to those early days—the shattered samples, the cold rejections, and the criticism from senior scientists. He maintains that “Conventional wisdom isn’t always correct, and it’s important to never give up—(almost) regardless of what others say.”




ici

CVS Health Exec: Payers Need to Stop Making Behavioral Health Providers Jump Through Hoops In Order to Participate in Value-Based Care

Value-based care contracting is especially difficult for behavioral health providers, Taft Parsons III, chief psychiatric officer at CVS Health/Aetna, pointed out during a conference this week.

The post CVS Health Exec: Payers Need to Stop Making Behavioral Health Providers Jump Through Hoops In Order to Participate in Value-Based Care appeared first on MedCity News.




ici

4 Things Employers Should Know About Psychedelic Medicines

During a panel discussion at the Behavioral Health Tech conference, experts shared the promise psychedelic medicines hold for mental health and why employers may want to consider offering them as a workplace benefit.

The post 4 Things Employers Should Know About Psychedelic Medicines appeared first on MedCity News.




ici

Tools to Boost Beneficial Bacteria Can Help Poultry Farms Fight Salmonella

Chicken products cause an estimated 1 in 7 of the nation’s human Salmonella illnesses each year, partly because the pathogen can easily contaminate the environments where birds are raised. To reduce the risk that contaminated meat will reach consumers, poultry companies need measures that control the bacterium on farms where chickens are bred and raised.




ici

FDA Proposal Will Not Sufficiently Curb Injudicious Use of Antibiotics in Food Animals

The Food and Drug Administration published a concept paper in early January that describes a preliminary proposal for how the agency will ensure that companies developing antibiotics for administration to animals establish defined, evidence-based durations of use for all medically important antibiotics.




ici

Impact of Trump and Harris on Prescription Drug Pricing

The upcoming U.S. presidential election is stirring discussions around healthcare, especially the cost of prescription drugs and the […]

The post Impact of Trump and Harris on Prescription Drug Pricing appeared first on World of DTC Marketing.



  • As I See It
  • Business of the drug industry
  • Cost of healthcare in the U.S.
  • in the news
  • Election & Pharma


ici

Impact of Trump on Drug Pricing Policies

With Trump’s victory, healthcare and the pharmaceutical industry could shift significantly. Based on Trump’s first-term policies, his administration […]

The post Impact of Trump on Drug Pricing Policies appeared first on World of DTC Marketing.



  • in the news
  • Changes in healthcare

ici

Trump names Musk to co-lead newly formed Department of Government Efficiency

WASHINGTON — US President-elect Donald Trump said on Nov 12 that Elon Musk and former Republican presidential hopeful Vivek Ramaswamy will lead the newly created Department of Government Efficiency. Musk and Ramaswamy "will pave the way for my Administration to dismantle Government Bureaucracy, slash excess regulations, cut wasteful expenditures, and restructure Federal Agencies", Trump said in a statement. Trump said their work would conclude by July 4, 2026, adding that a smaller and more efficient government would be a "gift" to the country on the 250th anniversary of the signing of the Declaration of Independence. Businessman and former Republican presidential candidate Vivek Ramaswamy attends Donald Trump's campaign event sponsored by conservative group Turning Point Action, in Las Vegas, Nevada, US, Oct 24, 2024. PHOTO: Reuters file The appointments reward two Trump supporters from the private sector.




ici

Taiwan businessman Tsao to sue Chinese officials over sanctions

TAIPEI — Taiwanese businessman Robert Tsao said on Nov 11 that he would sue in a Taiwan court senior Chinese officials over sanctions they had placed on him, saying he was seeking to counter China's intimidation of lawful activity. China, which claims Taiwan as its own territory, said in October it would punish and sanction Tsao, the retired founder of chipmaker United Microelectronics Corp (UMC), for alleged criminal and pro-Taiwan independence activities. China's Taiwan Affairs Office said the "Black Bear Academy" that Tsao has helped fund was seeking to incite separatism that would endanger cross-strait ties. Tsao, one of Taiwan's richest men who has pledged to provide millions to two civilian defence training programmes, told a press conference that China was threatening the lawful holding of political views in Taiwan and his personal safety. The lawsuit will be lodged in a Taipei court against Song Tao, head of China's Taiwan Affairs Office, and also the office's spokesman Chen Binhua. Taiwan courts have no jurisdiction in China and senior Chinese officials do not visit the island.




ici

Nowhere to Hide? Global Policing and the Politics of Extradition

U.S. power extends beyond the military and economic spheres to include policing. The United States has used its global policing power to capture terrorists, warlords, and drug kingpins. But extradition is not simply a bureaucratic tool. States’ geopolitical interests shape their willingness to cooperate with others in extraditing fugitives. 




ici

Terror threats keep me awake, Manmohan Singh told U.S. official



  • The India Cables

ici

&lsquo;Many Pakistans, so we need many Pakistan policies'

‘India does not want to play into the hands of terrorists by shunning dialogue.'



  • The India Cables

ici

The Electricity Sector and Climate Policy: A Discussion with Karen Palmer

Energy economist Karen Palmer, renowned for her research on the nation’s electric power sector, shared her insights on electricity regulation and deregulation, carbon pricing, and climate change policy in the latest episode of “Environmental Insights: Discussions on Policy and Practice from the Harvard Environmental Economics Program.”




ici

The Challenges Facing the Nation's Electricity Power Sector: A Conversation with Severin Borenstein

Energy economist Severin Borenstein, Professor of the Graduate School at the Haas School of Business at the University of California, Berkeley, discussed the many significant challenges facing the nation’s electricity power sector in the latest episode of “Environmental Insights: Discussions on Policy and Practice from the Harvard Environmental Economics Program.







ici

Integrating Solar Electricity into a Fossil Fueled System

Deploying renewable energy sources is the most promising approach to decarbonizing the power sector in China. However, the intermittency and non-dispatchable nature of wind and solar power pose significant challenges to grid stability, particularly when these sources reach high penetration rates. This study applies a unit commitment model to investigate the economic and environmental performance of load shaving strategies across different scenarios.




ici

CrissCross Expands Representative Payee Services to Serve as a National Resource for Qualified Beneficiaries - CrissCross Representative Payee Services

CrissCross Representative Payee Services




ici

Smart is Evolving: Efficient High-rise Changes Corporate Landscape with 'Urban Genius' Concept - Video OneTitle

Virtual tour of 350 Fifth, a new 20-story office building in one of the top-ranked U.S. cities for sustainable buildings. Pt. 1 Pittsburgh-Gateway to the World & 350 Fifth Urban Genius.




ici

Extended Stay America Partners With The Noerr Programs To Create The "Official Hotel of Santa Claus" - Santa Claus� Travel Secrets

Santa Claus and Extended Stay America, �Santa�s Official Hotel,� Partner to ease holiday travel woes. In time for the holiday season, the ultimate holiday travel guru shares holiday travel tips.




ici

JJ ABRAMS SOUGHT THE AUTHENTICITY OF SKELLIG MICHAEL FOR STAR WARS � THE FORCE AWAKENS - JJ Abrams sought the authenticity of Skellig Michael for Star Wars � The Force Awakens

JJ Abrams sought the authenticity of Skellig Michael for Star Wars � The Force Awakens








ici

La OEM, la FEMA, y el Ad Council dan inicio a la undécima versión anual del Mes Nacional de la Preparación en la ciudad de Nueva York - Waiting- NYC Spanish :30

Asegúrese que su familia tenga un punto de reunión para encontrarse en casos de emergencia. Visite N-Y-C punto gov diagonal ready N-Y o marque 311.




ici

El Departamento del Tesoro y el Departamento de Vivienda y Desarrollo Urbano de los Estados Unidos lanzan con el Ad Council nuevos anuncios de servicio público para ayudar a los propietarios de viviendas en dificultades - Esto es el por que :60

Esto es el por que :60




ici

Celebrando las tradiciones hispanas con la famosa chef Lorena García - Pork Tenderloin Sautéed (Lomo Saltado)

Lomo saltado: Esta receta está llena de exquisitos sabores y texturas que le harán la boca agua a toda la familia. Ingredientes: lomo de cerdo picado en tiras, saltado con papas blancas, pimiento amarillo, pimiento Cubanelle y tomates.




ici

El Departamento de Transporte de EE.UU. pone a disposición herramientas-y campaña para mejorar la seguridad de los niños a bordo de vehículos - Chairs :60

Chairs :60




ici

MundoFox estrena "¿Quién Mató a Patricia Soler?" el lunes 9 de febrero a las 9PM/8C - QMAPS Promo

MundoFox estrenará “¿Quién Mató a Patricia Soler?” el lunes 9 de febrero a las 9PM/8c.




ici

Lucero conducirá la primera edición de los "Latin American Music Awards" en vivo por TELEMUNDO el 8 de octubre a las 9pm/8c - Artistas en los primeros Latin American Music Awards 8 de oct. en TELEMUNDO

Artistas en los primeros Latin American Music Awards 8 de oct. en TELEMUNDO




ici

El Departamento de Transporte de los Estados Unidos, el Ad Council y el Television Bureau of Advertising se asocian para evitar las muertes causadas por conductores ebrios durante las fiestas de fin de año - Anuncio de servicio público para TV :

Anuncio de servicio público para TV :30




ici

Wheels Up Officially Unveiled First-Ever Pink Beechcraft King Air 350i Aircraft In Support Of Breast Cancer Awareness Month - The Wheels Up Pink Plane Unveiling

The Wheels Up Pink Plane is the first-ever pink Beechcraft King Air 350i. Proceeds benefit the Dubin Breast Center at Mount Sinai in New York City. Westchester County Airport, White Plains, NY